This inventor holds 1 USPTO granted patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: David Hardick: Innovator in Radiolabeled Compounds
Introduction
David Hardick is a notable inventor based in Margate, GB. He has made significant contributions to the field of radiolabeled compounds, which are essential for medical imaging and research. His work focuses on the development of innovative compounds that can aid in the diagnosis of neurodegenerative diseases.
Latest Patents
David Hardick holds 1 patent related to radiolabeled compounds. His patent describes compounds of formula I, wherein specific components are labeled with radionuclides such as H, C, and F. This invention is particularly useful for imaging alpha-synuclein and/or Abeta deposits in mammals, which is crucial for understanding and diagnosing conditions like Alzheimer's disease.
Career Highlights
David is currently employed at Hoffmann-La Roche Inc., a leading global healthcare company. His role involves research and development in the field of radiolabeled compounds, where he applies his expertise to create innovative solutions for medical imaging.
Collaborations
David has collaborated with several talented individuals in his field, including Edilio Borroni and Luca Claudio Gobbi. These collaborations have enhanced the research and development process, leading to advancements in the use of radiolabeled compounds.
Conclusion
David Hardick's contributions to the field of radiolabeled compounds demonstrate his commitment to innovation in medical imaging. His work not only advances scientific understanding but also has the potential to improve diagnostic techniques for neurodegenerative diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile